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Abstract: We report the workflow of immunogenetic pre-transplant testing and post-transplant monitoring in the case 
of a recipient immunized to human leucocyte antigens (HLA) who was waitlisted for heart transplantation. The 
recipient underwent heart transplantation across preformed HLA class I Donor Specific Antibodies (DSAs) detected by 
solid phase Luminex screening method but not by complement dependent cytotoxicity (CDC) screening method. The 
CDC lymphocyte crossmatch, which was performed retrospectively, was a weak positive. Post-transplant DSA 
monitoring by Luminex method revealed the decrease of HLA-A1, A25 and B57 DSAs with, at the same time, an 
increase of HLA-B8 DSA, as well as weak transient non-DSA HLA-DP antibodies. This case presents the importance 
of extensive immunogenetic testing and monitoring for identifying recipients with increased immunological risk for 
successful heart transplantation. 
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Heart transplantation is considered standard therapy for 
patients with end-stage heart failure when other 
medical treatments are not effective. While there has 
been much improvement in survival rates during the 
last five decades of heart transplantation, allograft 
rejection still remains a major cause of morbidity and 
mortality in the post-transplant period.
1
 Rejection of a 
transplanted heart can be caused by the presence of 
donor specific antibodies (DSAs), recipient's antibodies 
against the donor’s HLA antigens. They can be 
persistent in a recipient that was sensitized before 
transplantation through prior transplantation, 
transfusion or, in case of female recipients, pregnancy, 
or they can be formed after transplantation as de novo 
DSAs. Sensitized recipients have traditionally had high 
waitlist mortality due to unacceptable antigens that 
limit the available donor pool and increase wait time.
2
 
In case of kidney and bone marrow transplantation, the 
importance of HLA matching to avoid sensitization has 
been widely accepted; however, it is still disputed in 
heart transplantations. Currently, HLA matching is not 
widely accepted as a selection criterion for heart 
recipient choice for a few reasons. Firstly, there is not 
enough research with uniform results depicting clinical 
relevance of HLA matching in heart transplanting. 
Secondly, potential heart recipients usually have bad 
short-term prognosis, and waiting for a heart transplant 
with a high degree of HLA histocompatibility could be 
fatal for them. Furthermore, HLA matching of a 
potential heart donor with a recipient is limited by the 
small pool of heart donors, organ maintenance and 




Croatia is one of the eight member states of 
Eurotransplant, the biggest European international 
organization for organ exchange, participating in the 
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heart transplantation program with two transplant 
centres for which our centre is a full-service 
histocompatibility laboratory. Heart allocation within 
Eurotransplant is based on waiting time and urgency. 
Histocompatibility in terms of HLA matching is not 
considered, HLA typing and antibody screening are not 
mandatory for active status of the recipient on the 
waiting list. Thus, a local clinical protocol is 
established taking histocompatibility testing into 
account. Our centre policy includes mandatory HLA-A, 
B, DR molecular typing, CDC screening and the 
Luminex HLA antibody detection screening test at the 
time of the recipient registration on the waiting list. In 
case of an immunized (sensitized) recipients, Luminex 
screening is expanded with single antigen beads (SAB) 
testing in order to precisely define HLA class I and 
class II antibody specificities present in the recipient’s 
serum. Based on overall results, donor HLA antigens 
that should be avoided in a case of an organ offer are 
reported as a recommendation to the transplant 
clinicians. 
Measure of sensitization is expressed through 
percentage of Panel Reactive Antibodies (%PRA) and 
is calculated either based on the percentage of positive 
reactions in a panel of 50-100 individuals in 
Complement Dependent Cytotoxicity (CDC) test or 
calculated (cPRA; virtual PRA) by taking in the count 
frequency of the recipient’s unacceptable HLA alleles 
in the Eurotransplant donor population. The higher the 
PRA, the higher the probability of a recipient reacting 
immunologically against the donor population and 
giving a positive CDC lymphocyte crossmatch (CM), 
which can even in the case of heart recipient be 
considered as a contraindication for transplantation.
4
 
Wait time on the waitlist of sensitized heart transplant 
recipients can therefore be shortened by transplanting 
across positive DSAs and positive CM but at the cost 
of an increased risk of post-transplant antibody-
mediated rejection (AMR; humoral rejection), which 
presents a major threat to graft survival after heart 
transplantation, especially during the first 1-2 months 
after transplantation. AMR is a process where recipient 
antibodies ''attack'' donor HLA antigens on the surface 
of the transplanted organ, which leads to the activation 
of the complement cascade and the activation of innate 
and adaptive immune responses. This results in an 
inflammatory process that manifests itself as allograft 
dysfunction and possibly allograft rejection. For that 
reason, it is highly important to monitor levels of DSAs 
in sensitized recipients before and after transplantation 




Thresholds of Mean Fluorescence Intensity (MFI) in 
Luminex SAB testing of approximately 5000 for DSA 
against class I antibodies, 2000 against class II 
antibodies or an overall cut-off of 5000-6000 for any 
DSAs are taken to be predictive values for AMR.
7
 
Here, we report the results of immunogenetic pre-
transplant testing and post-transplant monitoring of a 
sensitized heart transplant recipient that was 
transplanted across Luminex detected DSAs and a 
weak positive CM. 
CASE REPORT 
A 67-year-old recipient with B positive blood type was 
registered in April 2017 on the Eurotransplant elective 
waiting list for heart transplantation. Prior to wait-
listing, immunogenetic testing was done according to 
standard protocol which includes molecular HLA 
typing and HLA antibody determination and 
identification by CDC and Luminex SAB. HLA-A, B, 
C, DR, DQ typing was performed by polymerase chain 
reaction - sequence specific primers (PCR-SSP) 
method (CareDx, Olerup SSP AB, Sweden). CDC 
antibody screening both before and after dithiothreitol 
(DTT) treatment was performed using a local panel of 
50 HLA-A, B, C, DR typed donors. Commercial 
Immucor’s LIFECODES LSA class I and class II 
Single Antigens tests (SA1 and SA2; Immucor 
Transplant Diagnostics Inc., Stamford, Connecticut, 
USA) were used for screening by Luminex method. 
Patient’s HLA typing was: HLA-A*11, *68; B*35, -; 
C*04, -; DRB1*08, *13; DQB1*03, *06. CDC 
screening was positive, the percentage of PRA was 24 
without DTT and 20% with DTT, pointing to the 
presence of IgG subclass of cytotoxic complement 
binding HLA antibodies of HLA-B7, B60 and B61 
specificity. The Luminex SA1 and SA2 test results 
showed the presence of HLA class I antibodies with 
MFI in the range 1000-16000. HLA-B7 antibody 
specificity had the highest MFI value, confirming the 
CDC antibody identification result. Complete HLA 
class I antibody Luminex profile pointed to the 
presence of antibodies specific for 163EW+73TE, 
113HN, 24T and 82LR epitopes. HLA class II 
antibodies were negative. 
Recipient received a heart offer in September 2018 
from a cadaveric donor, blood type B, with HLA 
typing HLA-A*01, *25; B*08, *57; C*06, *07; 
DRB1*11, *13; DQB1*03, *06. 
Antibody profile was analyzed for mismatched donor 
antigens HLA-A1, A25, B8, B57, Cw6, Cw7 and 
DR11, revealing positive reactions in Luminex for 
HLA-A1, A25, B8 and B57 specificities, with MFI 
values in the range 1100 (HLA-A1) to 2500 (HLA-
B57). The analysis of pre-transplant CDC screening 
results indicated that cytotoxic antibodies are not 
present for any of the donor’s HLA-A and HLA-B MM 
antigens. Due to logistic conditions, CDC CM was 
carried out retrospectively, on post-transplant day 1. 
The recipient’s pre-transplant serum was tested against 
T and B lymphocytes of the donor in a crossmatch 
reaction, following the same procedure as the one used 
for CDC screening. The result of CM was a “weak 
positive” meaning that cytotoxic antibodies present in 
the patient’s serum were reacting to 10-20% of donor 
lymphocytes. Taking into consideration pre-transplant 
results of weak positive DSAs in Luminex screening 
and weak positive CDC CM, extensive protocoled 
post-transplant monitoring, as well as monitoring by 
indication, was introduced. CDC antibody monitoring 
showed an increase of %PRA shortly after the 
transplantation, with a result of PRA 62% at post- 
transplant day 30 and day 60, while afterwards steadily 
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Figure 1. Results of CDC screening reported as %PRA throughout the post-transplant follow-up period and Luminex single antigen beads 
test results showing Mean Fluorescence Intensity (MFI) values for Donor Specific Antibodies in recipient serum after transplantation. Cut-off 
MFI value is 1000. 
 
 
decreasing, with the latest result of PRA 0% 18 months 
after the transplantation (Figure 1). Luminex screening 
showed a MFI decrease for HLA-A1, A25 and B57 
antibodies at 1 month after the transplantation, 
remaining either low positive or negative in all further 
testings up to 18 months post-transplant. In contrast, 
HLA-B8 antibody reactions in SAB assay were 
increasing in the early post-transplant period, reaching 
a peak value of MFI 6000 two months after the 
transplantation. MFI values at four and six months 
post-transplant were still high (3700 and 4400) but 
subsequently started to steadily decrease, but never 
reaching negative result (Figure 1, Figure 2). Class II 
antibodies that were negative pre-transplant, turned to 
be weak positive for DP18 antibodies at four months 
post-transplant. HLA-DP typing of both the recipient 
and the donor was urgently performed, the antibodies 
turned out not to be DSAs, as the recipient and the 
donor were HLA-DP identical. HLA-DP antibody 
positivity remained in three further testing, and 




HLA sensitization prior to heart transplantation is a 
well-established risk factor for a higher incidence of 
rejection as well as for worse organ and recipient 
survival. Thus, precise and timely detection of HLA 
antibody profile prior to waitlisting, definition of DSAs 
at the time of organ offer and subsequent DSA 
monitoring in case of organ acceptance across positive 
DSAs is vital for evaluating the recipient’s humoral 
immune status pre- and post-transplantation. The 
recipient presented in this paper was sent for pre-
transplant immunogenetic testing as a heart transplant 
candidate two months prior to registration on the 
Eurotransplant waiting list. CDC screening result 
revealed that the patient has cytotoxic HLA antibodies 
belonging to HLA-B7 cross-reactive group (CREG). 
Luminex SAB screening confirmed serologically 
obtained results, with an extension of antibody profile 
to 163EW+73TE, 113HN, 24T and 82LR epitopes. We 
assume blood transfusions as probable historical 
immunizing event(s), as this was a male recipient 
without previous transplantations and without a left 
ventricular assist device, which is also reported to be 
the cause of HLA sensitization in heart recipients.
8
 
Screening results obtained with the serum sample taken 
immediately before the transplantation were 
concordant with these historical screening results.  
Avoiding DSA at transplant is a desirable objective, 
although not always possible to attain, particularly in 
highly sensitized (HS) recipients or in recipients in 
clinically high urgent need of transplantation. With a 
cPRA of 98%, DSA negative transplantation was 
hardly feasible for this recipient, and all the efforts 
were directed towards avoiding transplantation with 
CDC identified DSAs, above all antigens from the 
HLA-B7 CREG group. The heart offer that was 
accepted and the heart transplantation performed 
fulfilled these criteria. However, the transplantation 
was not immunologically ideal, as it was performed 
across weak positive reactions for both donor’s 
mismatched HLA-A and HLA-B antigens. Even more, 
retrospectively performed CDC CM was also a weak 
positive, although it was not an expected result, as 
Luminex reactions were not in the range that is 
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Figure 2. Patient’s timeline with main immunological events and results of testings before and after transplantation (Recipient and donor 
HLA typing, mismatched alleles and antibody specificities in CDC screening and solid phase Luminex screening method). DSA - Donor-
Specific Antibody, MM - Mismatch, MFI - Mean Fluorescence Intensity, CREG - Cross-Reactive Group. 
 
 
proven to correlate with CM positivity. Namely, 
literature data,
9
 as well as our own validation results, 
show that an MFI range 2000-8500 for DSAs towards 
HLA-A and/or HLA-B is a predictor for a negative 
CDC CM. In our recipient, all four DSAs had MFI 
falling into this range; moreover, the values were 
mostly below MFI 2000. One possible explanation can 
be that weak reactions were against the Bw4 public 
epitope present in the donors’ cells, as anti-Bw4 
antibodies, proven to be present in the recipient serum 
by Luminex assay, might not recognize all Bw4 
positive molecules, resulting in weak positive reactions 
in cytotoxicity testing. Intensive post-transplantation 
monitoring revealed different behavior of pre-
transplant DSAs. Three DSAs, HLA-A1, A25 and B57, 
decreased in the mean of MFI values shortly after the 
transplantation, never again reaching pre-transplant 
level, and they all turned to be steadily negative 6 
months after transplantation until the last check-up in 
February 2020. In contrast, HLA-B8 antibody 
increased shortly after transplantation, and the increase 
was correlated with the increase of overall positive 
reactions, suggesting that the recipient is at 
immunological risk for AMR. The recipient was treated 
with plasmapheresis and intravenous immunoglobulins 
(IVIg), as well as with four cycles of extracorporeal 
photopheresis, which was accompanied with the 
decrease of HLA-B8 antibody level, but the reactions 
never reached a stable low or negative value, remaining  
prone to MFI variability (Figure 2).  
The transient appearance of HLA class II antibodies of 
HLA-DP specificities that turned out to be non-DSA, 
were detected shortly after the overall increase of HLA 
class I antibodies and might be the reappearance of 
previous pre-transplant HLA-DP sensitization. 
This case emphasizes the importance of careful and 
well-timed immunogenetic testing and monitoring 
before and after transplantation as new and preformed 
HLA DSAs and non-DSAs need to be adequately 
interpreted in terms of increased immunological risk, 
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